Clinical Trial Update: Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating short-course definitive chemoradiotherapy with camrelizumab given concurrently or as adjuvant therapy for locally advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Ning Jiang, M.D./Ph.D. | Conditions: Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING